Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $52.80.

Several equities analysts have commented on COLL shares. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a research report on Friday, January 9th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Barclays reduced their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th.

Collegium Pharmaceutical Stock Down 2.8%

Shares of NASDAQ COLL opened at $45.60 on Friday. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 28.32 and a beta of 0.60. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79. The stock has a 50-day moving average price of $47.10 and a two-hundred day moving average price of $39.14.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.89 by $0.36. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business had revenue of $209.36 million during the quarter, compared to analysts’ expectations of $191.25 million. During the same period in the prior year, the company earned $1.61 EPS. The firm’s quarterly revenue was down 18.9% compared to the same quarter last year. As a group, analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the transaction, the director owned 52,629 shares in the company, valued at approximately $2,475,141.87. The trade was a 6.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the sale, the chief financial officer owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 51,250 shares of company stock valued at $2,235,352. Company insiders own 2.51% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Amundi raised its stake in Collegium Pharmaceutical by 302.1% during the 1st quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company’s stock worth $1,816,000 after buying an additional 47,024 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Collegium Pharmaceutical by 3.1% during the second quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company’s stock valued at $7,389,000 after acquiring an additional 7,614 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Collegium Pharmaceutical by 90.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock valued at $6,844,000 after purchasing an additional 92,898 shares during the period. Rhumbline Advisers lifted its stake in shares of Collegium Pharmaceutical by 3.1% in the first quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company’s stock valued at $3,332,000 after buying an additional 3,400 shares in the last quarter. Finally, Eastern Bank raised its holdings in shares of Collegium Pharmaceutical by 487.5% in the 3rd quarter. Eastern Bank now owns 54,843 shares of the specialty pharmaceutical company’s stock worth $1,919,000 after acquiring an additional 45,508 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.